This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Recent Abstracts
AUA 2011 - Current treatment patterns and characteristics of castration resistant prostate cancer (CRPC) patients; a European survey - Session Highlights
May 17, 2011
AUA 2011 - Can an early PSA rule out subsequent advanced prostate cancer? Long term risk of advanced cancer in men with low PSA levels at age below 50 - Session Highlights
May 17, 2011
AUA 2011 - The value of computed tomography in detecting prostate cancer lymph node metastasis is limited even in contemporary patients with very high risk of nodal involvement - Session Highlights
May 17, 2011
AUA 2011 - Men with isolated high grade prostatic intraepithelial neoplasia (HGPIN) have a high risk of prostate cancer in long-term follow-up: Results from a prospective multicenter, randomized, placebo-controlled prostate cancer prevention trial - Sessi
May 17, 2011
AUA 2011 - Prostate cancer detection rates, risk factors, and distribution with transperineal mapping template prostate biopsy: initial single institution experience - Session Highlights
May 17, 2011
AUA 2011 - Potency outcomes in patients who had multiple biopsies before radical prostatectomy for the treatment of localized prostate cancer - Session Highlights
May 17, 2011
AUA 2011 - Evaluation of the prostate health index (PHI) in the 2 to 4, and 4 to 10 ng/ml PSA ranges: Results from a multi-site, prospective, clinical evaluation - Session Highlights
May 17, 2011
AUA 2011 - 11C-choline PET/CT versus transrectal ultrasound-guided prostate biopsy to diagnose locally recurrent prostate cancer following radiation therapy - Session Highlights
May 17, 2011
AUA 2011 - How soon can we identify men at high risk for prostate cancer death? An early surveillance strategy for prostate cancer - Session Highlights
May 17, 2011
AUA 2011 - Smoking linked to biochemical recurrence of prostate cancer - Press Release
May 17, 2011
AUA 2011 - Building a better cancer test: Updates on new biomarkers and genetic assays for bladder and prostate cancers - Press Release
May 17, 2011
AUA 2011 - Extended sampling biopsies, MRI show promise in managing low-risk prostate cancer - Press Release
May 16, 2011
AUA 2011 - Abiraterone demonstrates effective results with favorable safety profile in men with castration-resistant advanced prostate cancer - Press Release
May 16, 2011
AUA 2011 - Prostate cancer: To treat, not to treat and when to treat? - Press Release
May 16, 2011
AUA 2011 - Clusterin antisense inhibitor OGX-011 synergizes activity of second generation anti-androgen, MDV3100, in castrate resistant prostate cancer model - Session Highlights
May 16, 2011
AUA 2011 - Differential expression of RANKL and osteoprotegerin in patients with clinically localized prostate cancer - Session Highlights
May 16, 2011
AUA 2011 - Pre-operative urinary prostate cancer gene 3 (PCA3) is predicting pathologically confirmed small volume and insignificant prostate cancer - Session Highlights
May 16, 2011
AUA 2011 - Implications of surgical margin status on prostate cancer-specific survival - Session Highlights
May 16, 2011
AUA 2011 - Phase 1-2 study of MDV3100 in pre-and post-docetaxel advanced prostate cancer: long-term efficacy results - Session Highlights
May 16, 2011
AUA 2011 - Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A number-needed-to-treat (NNT) analysis - Session Highlights
May 16, 2011
Page 1409 of 1447
Start
Prev
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free